The Food and Drug Administration said July 20 that it has approved Afinitor (everolimus) for use in combination with Aromasin (exemestane) to treat certain postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer.
Afinitor is a product of East Hanover, N.J.-based Novartis Pharmaceuticals Corp. (part of Swiss company Novartis AG). The agency said the drug combination is intended for use in women with recurrence or progression of their cancer after treatment with Femara (letrozole) or Arimidex (anastrozole). Aromasin is made by Pfizer, Femara is made by Novartis, and Arimidex is an AstraZeneca product.
FDA said breast cancer is the second-leading ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.